EN

Translate:

Hours of Operation: Monday Thru Friday 7:00am - 4:00pm


Completed Studies


Here is a list of medical research studies that we have completed over the years:


1.- A Phase III, randomized, double-blind, placebo-controlled study 

To investigate the efficacy and safety of the Xaracoll Bupivicaine implant

(300mg Bupivicaine Hydrochloride) After open laparotomy Hernioplasty.

Sponsor: Innocoll

Completed: June 2016


2.- A randomized, double-blind, multicenter, superiority, placebo-controlled, phase 3 study of Pexiganan Cream 0.8% Applied twice daily for 14 days in the treatment

Of Adults with Mild infections of Diabetic Foot Ulcers. 

Sponsor: Dipexium 

Completed: August 2016


3.- A Phase 3, randomized, double-blind study comparing ABT-494 once

Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX- Naïve

Subjects with moderately to severely active rheumatoid arthritis.

Sponsor: Abbvie 

Completed: October 2017


4.- A  phase 3, randomized, double-blind study comparing ABT-494 to

Placebo and to Adalimumab in Subjects with Moderately to Severely

Active Rheumatoid Arthritis who are on a stable background of 

Methotrexate (MTX) and who have an inadequate response to MTX

(MTX-IR).

Sponsor: Abbvie 

Completed: November2017


5.- A Multicenter, randomized, double-blind, crossover study to assess the 

Injection Site Pain Associated with a Modified Etanercept Formulation in 

Adult subjects with either Rheumatoid Arthritis or Psoriatic Arthritis.

Sponsor: Amgen

Completed: November 2017


6.- A randomized, double-blind, double-dummy, Multicenter, Active-controlled study

To evaluate the efficacy and safety of Vedolizumab IV Compared to Adalimumab SC

In subjects with ulcerative Colitis.

Sponsor: Takeda 

Completed: January 2018


7.- Randomized, Double-blind, Multicenter, 3-Stage, Efficacy and Safety

Study of NI-071 and US Licensed Remicade® (Infliximab) for the treatment

Of patients with Rheumatoid Arthritis.

Sponsor: Nichi-Iko Pharmaceuticals

Completed: March 2018


8.- A  phase III, double-blind, randomized, long-term, placebo-controlled,

Multicenter, study evaluating the safety and efficacy of Obeticholic Acid

In subjects with non-alcoholic steatohepatitis.

Sponsor: Intercept 

Completed: July 2018


9.- A phase III, randomized, open-label, comparative safety and efficacy

Trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in 

Subjects with iron deficiency anemia and non-dialysis-dependent

Chronic kidney disease.

Sponsor: Pharmacosmos 

Completed: September 2018


10.-     A randomized, double-blind, placebo-controlled, parallel group

Study of Patiromer for the enablement of SpironolactoneUse for Blood

Pressure Control in Patients with Resistant HypertensionAnd Chronic Kidney 

Disease: Evaluation of Safety and Efficacy (AMBER)

Sponsor: Relypsa 

Completed: March 2019


11.-   A randomized parallel-group, placebo-controlled, double-blind, 

multi-center trial to evaluate the efficacy and safety of the oral 

sGC stimulator vericiguat to improve physical functioning in

activities of daily living in patients with heart failure and preserved 

ejection fraction (VITALITY-HFpEF).

Sponsor: Bayer  

Completed: April 2019


12.-   Evaluation of the Performance of the Clinical Genomics Colvera

Test in the Detention of Disease recurrence in Patients Diagnosed

With Colorectal Cancer.-NOVA

Sponsor: Clinical Genomics 

Completed: August 2019


13.-   A randomized, controlled double-blind study comparing the efficacy

And safety of Orelvo (voclosporin) (23.7mg twice daily) With Placebo

In Achieving Renal response in subjects with Active Lupus Nephritis

Sponsor: Aurinia Pharmaceuticals 

Completed: January 2020


14.-   Phase III, double-blind, randomized, placebo controlled, multicenter, and study

To assess the safety and efficacy of vm202 to treat chronic nonhealing foot

Ulcers in diabetic patients with concomitant peripheral arterial disease (PAD)

Sponsor: VM Biopharma  

Completed: January 2020